Broadcast

e-SPACE CRM 2026 – Day Two

Shelley Zieroth, Shahzeb Khan, João Pedro Ferreira

Broadcast

e-SPACE CRM 2026 – Day One

Shelley Zieroth, Shahzeb Khan, João Pedro Ferreira

Broadcast

Breakthrough Mineralocorticoid Receptor Agonists in Cardiovascular Care

Vijay Chopra, Javed Butler, Dinesh Khullar , et al

Watch time: 1h 4m 2s

Broadcast

Breakthrough Mineralocorticoid Receptor Agonists in Cardiovascular Care

Vijay Chopra, Javed Butler, Dinesh Khullar , et al

Watch time: 1h 4m 2s

About

Hypertension is the most common modifiable risk factor for cardiovascular disease and death, and lowering blood pressure with antihypertensive drugs reduces target organ damage and prevents cardiovascular disease outcomes.

Most hypertensive patients will need a combination of antihypertensive agents to achieve the therapeutic goals. Recent guidelines recommend initiating treatment with two drugs in those patients with a systolic blood pressure >20 mmHg and/or a diastolic blood pressure >10 mmHg above the goals, and in those patients with high cardiovascular risk. In addition, approximately 25% of patients will require three antihypertensive agents to achieve the therapeutic targets.

Articles

Use of Heart Failure-Exacerbating Medications among Heart Failure Patients in a Tertiary Referral Centre in Malaysia

Published:

25 April 2023

Citation:

European Cardiology Review 2023;18:e37.

APSC Consensus on OSA in CVD Patients

Published:

20 June 2022

Citation:

European Cardiology Review 2022;17:e16.

Baroreflex Activation Therapy for Resistant Hypertension and Heart Failure

Published:

07 February 2020

Citation:

US Cardiology Review 2019;13(2):83–7.

Recognition, Diagnosis, and Management of Heart Failure with Preserved Ejection Fraction

Citation:

US Cardiology Review 2018;12(1):8–12.